Social network
Our responsibility

Toward tuberculosis elimination

Tuberculosis (TB) is one of the deadliest infectious diseases in the world. In 2015, there were 10.4 million new cases causing 1.8 million deaths worldwide, most of them occurring in developing countries.

In about 9 out of 10 infected people, tuberculosis will remain latent1. However, the risk of developing an active form of TB is much higher for individuals whose immune system is compromised (due to HIV, treatment with immunosuppressant, malnutrition, diabetes, etc.).

 

Focusing on the treatment of latent tuberculosis infection

To eliminate tuberculosis, we have not only to treat the disease (active tuberculosis), but we must prevent its development in patients infected with latent tuberculosis (sleeping form of the disease). Especially for high risk populations such as HIV infected persons and children under 5.

 

Simplifying treatment

Sanofi has collaborated with the Centers for Disease Control and Prevention (CDC) of Atlanta (USA) and their international network to simplify the treatment of latent tuberculosis thus reducing a daily dosing regimen for 6-9 months to a weekly dosing regimen for only 3 months. This collaboration resulted, late 2014, in the approval by US FDA of a shortened treatment.

 

Fighting against resistant forms

Sanofi collaborates with the TB Alliance, to identify new medicines that are active against all forms of tuberculosis, including multi-resistant forms.

Discover the video Understanding Active & Latent Tuberculosis:

 

For more information:

 

 

References :

  1. WHO Media Center, Tuberculosis, Fact sheet Reviewed March 2017